Brind.
  1. AstraZeneca and Autolus Therapeutics are driving investment and innovation in cancer treatment within the US market.

Autolus Therapeutics reported positive clinical trial results for its next-generation T cell therapies, including AUCATZYL®.

1 report, 1 independent Updated Jul 21
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Autolus Therapeutics reported positive clinical trial results for its next-generation T cell therapies, including AUCATZYL®.

Who's involved

What this event is mainly about
Autolus Therapeutics

Keep exploring

Part of

AstraZeneca and Autolus Therapeutics are driving investment and innovation in cancer treatment within the US market. All 1 developments

The entities involved

Coverage

Newest first; wire copies grouped
  • GlobeNewswireAutolus Therapeutics’ CAR T Therapy AUCATZYL® (Obecabtagene Autoleucel) Granted European Marketing Authorization for Adult Patients (age 26 and older) with Relapsed or Refractory B-Cell Precursor Acut